Neumora Therapeutics IncNASDAQ:NMRA
- LAST PRICE9.7800
- TODAY'S CHANGE (%)-0.1700 (-1.7085%)
- Bid / Lots8.3100/ 1
- Ask / Lots9.9900/ 1
- Open / Previous Close9.8400 / 9.9500
- Day Range
- 52 Week Range
- Volume376,381
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRA |
|---|---|---|
| 09:32 ET | 870 | 9.985 |
| 09:34 ET | 200 | 9.995 |
| 09:38 ET | 300 | 9.99 |
| 09:39 ET | 200 | 9.86 |
| 09:41 ET | 100 | 10.13 |
| 09:43 ET | 200 | 9.94 |
| 09:45 ET | 700 | 10.06 |
| 09:48 ET | 8606 | 10.025 |
| 09:50 ET | 1824 | 10.18 |
| 09:52 ET | 4065 | 10.03 |
| 09:54 ET | 9018 | 9.95 |
| 09:56 ET | 500 | 9.975 |
| 09:57 ET | 1100 | 9.93 |
| 09:59 ET | 300 | 9.85 |
| 10:01 ET | 470 | 9.943 |
| 10:08 ET | 400 | 9.9 |
| 10:10 ET | 2119 | 10.01 |
| 10:12 ET | 700 | 10.03 |
| 10:14 ET | 3373 | 10.03 |
| 10:15 ET | 3772 | 9.94 |
| 10:21 ET | 1482 | 9.945 |
| 10:26 ET | 100 | 9.99 |
| 10:28 ET | 962 | 10.07 |
| 10:30 ET | 1000 | 10.07 |
| 10:32 ET | 2820 | 10.09 |
| 10:33 ET | 100 | 10.03 |
| 10:35 ET | 300 | 10.02 |
| 10:39 ET | 1996 | 10.08 |
| 10:42 ET | 200 | 10.11 |
| 10:44 ET | 4100 | 9.96 |
| 10:48 ET | 100 | 9.94 |
| 10:50 ET | 482 | 9.91 |
| 10:51 ET | 100 | 9.965 |
| 10:53 ET | 300 | 10.02 |
| 10:55 ET | 301 | 9.955 |
| 10:57 ET | 801 | 10 |
| 11:00 ET | 3381 | 10 |
| 11:02 ET | 3386 | 9.89 |
| 11:04 ET | 100 | 9.83 |
| 11:06 ET | 100 | 9.83 |
| 11:08 ET | 860 | 9.855 |
| 11:09 ET | 800 | 9.84 |
| 11:11 ET | 574 | 9.88 |
| 11:13 ET | 600 | 9.88 |
| 11:15 ET | 761 | 9.89 |
| 11:18 ET | 600 | 9.89 |
| 11:20 ET | 100 | 9.89 |
| 11:22 ET | 402 | 9.85 |
| 11:24 ET | 400 | 9.87 |
| 11:26 ET | 1547 | 9.9 |
| 11:27 ET | 300 | 9.89 |
| 11:29 ET | 6670 | 9.72 |
| 11:31 ET | 1435 | 9.78 |
| 11:33 ET | 200 | 9.7668 |
| 11:36 ET | 200 | 9.76 |
| 11:38 ET | 200 | 9.7675 |
| 11:42 ET | 300 | 9.77 |
| 11:44 ET | 300 | 9.8 |
| 11:45 ET | 300 | 9.8 |
| 11:47 ET | 300 | 9.8 |
| 11:49 ET | 600 | 9.8 |
| 11:51 ET | 4022 | 9.675 |
| 11:54 ET | 400 | 9.67 |
| 11:56 ET | 100 | 9.67 |
| 12:00 ET | 550 | 9.62 |
| 12:02 ET | 1300 | 9.58 |
| 12:03 ET | 3261 | 9.65 |
| 12:05 ET | 487 | 9.67 |
| 12:07 ET | 100 | 9.72 |
| 12:09 ET | 400 | 9.72 |
| 12:12 ET | 1198 | 9.8 |
| 12:14 ET | 500 | 9.8 |
| 12:16 ET | 2045 | 9.77 |
| 12:21 ET | 300 | 9.78 |
| 12:23 ET | 3100 | 9.75 |
| 12:25 ET | 100 | 9.735 |
| 12:32 ET | 400 | 9.69 |
| 12:36 ET | 2513 | 9.74 |
| 12:39 ET | 100 | 9.74 |
| 12:41 ET | 200 | 9.71 |
| 12:43 ET | 100 | 9.74 |
| 12:45 ET | 2356 | 9.81 |
| 12:48 ET | 3600 | 9.73 |
| 12:50 ET | 100 | 9.69 |
| 12:52 ET | 100 | 9.72 |
| 12:54 ET | 100 | 9.68 |
| 12:56 ET | 100 | 9.67 |
| 12:57 ET | 454 | 9.65 |
| 12:59 ET | 2894 | 9.76 |
| 01:01 ET | 400 | 9.77 |
| 01:03 ET | 300 | 9.755 |
| 01:06 ET | 100 | 9.78 |
| 01:08 ET | 200 | 9.78 |
| 01:10 ET | 100 | 9.78 |
| 01:12 ET | 200 | 9.8 |
| 01:14 ET | 800 | 9.79 |
| 01:15 ET | 1378 | 9.775 |
| 01:17 ET | 254 | 9.76 |
| 01:19 ET | 1493 | 9.71 |
| 01:26 ET | 526 | 9.79 |
| 01:30 ET | 223 | 9.755 |
| 01:32 ET | 334 | 9.755 |
| 01:33 ET | 300 | 9.755 |
| 01:37 ET | 1436 | 9.69 |
| 01:42 ET | 225 | 9.68 |
| 01:46 ET | 3369 | 9.735 |
| 01:48 ET | 1262 | 9.77 |
| 01:50 ET | 432 | 9.77 |
| 01:51 ET | 669 | 9.76 |
| 01:53 ET | 500 | 9.78 |
| 01:55 ET | 100 | 9.79 |
| 01:57 ET | 1918 | 9.77 |
| 02:04 ET | 300 | 9.765 |
| 02:06 ET | 4619 | 9.695 |
| 02:08 ET | 1262 | 9.75 |
| 02:13 ET | 100 | 9.75 |
| 02:22 ET | 5124 | 9.75 |
| 02:24 ET | 848 | 9.78 |
| 02:26 ET | 1501 | 9.795 |
| 02:27 ET | 200 | 9.79 |
| 02:29 ET | 320 | 9.77 |
| 02:31 ET | 1716 | 9.81 |
| 02:36 ET | 371 | 9.805 |
| 02:38 ET | 1246 | 9.785 |
| 02:40 ET | 821 | 9.785 |
| 02:42 ET | 400 | 9.785 |
| 02:44 ET | 2564 | 9.77 |
| 02:45 ET | 200 | 9.77 |
| 02:47 ET | 509 | 9.8 |
| 02:49 ET | 500 | 9.8 |
| 02:51 ET | 1732 | 9.78 |
| 02:54 ET | 300 | 9.77 |
| 02:56 ET | 1000 | 9.795 |
| 02:58 ET | 2556 | 9.77 |
| 03:00 ET | 2940 | 9.78 |
| 03:02 ET | 100 | 9.77 |
| 03:03 ET | 623 | 9.79 |
| 03:05 ET | 100 | 9.805 |
| 03:07 ET | 700 | 9.83 |
| 03:09 ET | 1217 | 9.815 |
| 03:12 ET | 910 | 9.8 |
| 03:14 ET | 2596 | 9.79 |
| 03:16 ET | 400 | 9.795 |
| 03:18 ET | 400 | 9.78 |
| 03:20 ET | 300 | 9.79 |
| 03:21 ET | 4490 | 9.79 |
| 03:25 ET | 400 | 9.78 |
| 03:27 ET | 600 | 9.795 |
| 03:30 ET | 200 | 9.78 |
| 03:32 ET | 1290 | 9.8 |
| 03:34 ET | 6413 | 9.73 |
| 03:36 ET | 477 | 9.73 |
| 03:38 ET | 512 | 9.73 |
| 03:39 ET | 600 | 9.73 |
| 03:41 ET | 1831 | 9.71 |
| 03:43 ET | 3271 | 9.74 |
| 03:45 ET | 300 | 9.75 |
| 03:48 ET | 1000 | 9.74 |
| 03:50 ET | 5993 | 9.73 |
| 03:52 ET | 4026 | 9.74 |
| 03:54 ET | 7514 | 9.75 |
| 03:56 ET | 6998 | 9.73 |
| 03:57 ET | 2131 | 9.71 |
| 03:59 ET | 31569 | 9.78 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neumora Therapeutics Inc | 1.6B | -6.3x | --- |
Kura Oncology Inc | 1.6B | -9.6x | --- |
Belite Bio Inc | 1.5B | -42.5x | --- |
Spyre Therapeutics Inc | 1.6B | -0.4x | --- |
Edgewise Therapeutics Inc | 1.6B | -11.4x | --- |
Soleno Therapeutics Inc | 1.5B | -15.8x | --- |
Company Information
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
- Phone
- 857-760-0900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Founder
- Paul Berns
- President, Chief Executive Officer, Director
- Henry Gosebruch
- Co-Founder, Chief Operating Officer
- Carol Suh
- Chief Financial Officer
- Joshua Pinto
- Chief Strategy Officer
- Daljit Aurora
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 159.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.55 |
Book Value | $2.95 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
